Works against MS with the immune system for the long term
Works against MS with the immune system for the long term
 
Call Shared Solutions®
1-800-887-8100
support. knowledge. answers.
 

Important Safety Information

  • COPAXONE® (glatiramer acetate injection) is indicated for the reduction of the frequency of relapses in relapsing-remitting multiple sclerosis, including patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis

Important Safety Information About COPAXONE®

  • The most common side effects of COPAXONE® are redness, pain, swelling, itching, or a lump at the site of injection, flushing, rash, shortness of breath, and chest pain. These reactions are usually mild and seldom require professional treatment. Be sure to tell your doctor about any side effects
  • Some patients report a short-term reaction right after injecting COPAXONE® . This reaction can involve flushing (feeling of warmth and/or redness), chest tightness or pain with heart palpitations, anxiety, and trouble breathing. These symptoms generally appear within minutes of an injection, last about 15 minutes, and go away by themselves without further problems
  • A permanent indentation under the skin at the injection site may occur, due to a local destruction of fat tissue. Be sure to follow proper injection technique and inform your doctor of any skin changes
  • After you inject COPAXONE®, call your doctor right away if you develop hives, skin rash with irritation, dizziness, sweating, chest pain, trouble breathing, severe pain at the injection site or other uncomfortable changes in your general health. Do not give yourself any more injections until your doctor tells you to begin again

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/Safety/Medwatch, or call 1-800-FDA-1088.

Reference:
  1. IMS Health National Prescription Audit, February 2010. Data is proprietary to IMS Health.
  2. Ford C, Goodman AD, Johnson K, et al. Mult Scler. 2010;16(3):342-350.
  3. Data on file. Teva Neuroscience, Inc.

COP100005001/100889